M. Keklik Et Al. , "Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation," Annals of Hematology , vol.102, no.6, pp.1537-1547, 2023
Keklik, M. Et Al. 2023. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Annals of Hematology , vol.102, no.6 , 1537-1547.
Keklik, M., Deveci, B., Celik, S., Deniz, K., Gönen, Z. B., Zararsız, G., ... Saba, R.(2023). Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Annals of Hematology , vol.102, no.6, 1537-1547.
Keklik, Muzaffer Et Al. "Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation," Annals of Hematology , vol.102, no.6, 1537-1547, 2023
Keklik, Muzaffer Et Al. "Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation." Annals of Hematology , vol.102, no.6, pp.1537-1547, 2023
Keklik, M. Et Al. (2023) . "Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation." Annals of Hematology , vol.102, no.6, pp.1537-1547.
@article{article, author={Muzaffer Keklik Et Al. }, title={Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation}, journal={Annals of Hematology}, year=2023, pages={1537-1547} }